Only minimally involved in SBIR with a single Phase I some years after founding, since 1996 Comparative Biosciences Inc. has functioned as a preclinical contract research organization (CRO) providing expert, quality contract research services to all sectors of the biomedical community. Extensive experience in the biotechnology and pharmaceutical industries provided personnel an extensive track record in preclinical research and drug development capabilities. Also having the benefit of having an on site board-certified pathologist for evaluation and reporting of all the histology work done here, the firm's n-site histology laboratory has offered routine histopathology, special stains, immunohistochemistry (IHC), plastics, GLP antibody tissue cross reactivity (TCR), and histomorphometry services with quick turn around times. In August 2020, it was announced that Genesis Biotechnology Group acquired Comparative Biosciences for an undisclosed sum.
